X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs CIPLA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH CIPLA PANACEA BIOTECH/
CIPLA
 
P/E (TTM) x 24.8 37.6 65.9% View Chart
P/BV x 3.3 3.9 86.2% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   CIPLA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
CIPLA
Mar-17
PANACEA BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs149622 23.9%   
Low Rs82458 18.0%   
Sales per share (Unadj.) Rs84.1181.9 46.3%  
Earnings per share (Unadj.) Rs-18.312.9 -142.2%  
Cash flow per share (Unadj.) Rs-6.729.3 -22.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.7155.7 53.8%  
Shares outstanding (eoy) m61.25804.51 7.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.0 46.2%   
Avg P/E ratio x-6.342.0 -15.0%  
P/CF ratio (eoy) x-17.218.4 -93.6%  
Price / Book Value ratio x1.43.5 39.8%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m7,074434,516 1.6%   
No. of employees `0002.823.0 11.9%   
Total wages/salary Rs m1,44926,338 5.5%   
Avg. sales/employee Rs Th1,874.16,349.1 29.5%   
Avg. wages/employee Rs Th527.01,143.0 46.1%   
Avg. net profit/employee Rs Th-407.7449.3 -90.7%   
INCOME DATA
Net Sales Rs m5,154146,302 3.5%  
Other income Rs m1002,287 4.4%   
Total revenues Rs m5,254148,589 3.5%   
Gross profit Rs m-76624,758 -3.1%  
Depreciation Rs m71113,229 5.4%   
Interest Rs m1,5031,594 94.3%   
Profit before tax Rs m-2,88112,222 -23.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6-70 8.2%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m171,798 0.9%   
Profit after tax Rs m-1,12110,354 -10.8%  
Gross profit margin %-14.916.9 -87.9%  
Effective tax rate %-0.614.7 -4.0%   
Net profit margin %-21.87.1 -307.4%  
BALANCE SHEET DATA
Current assets Rs m3,81087,370 4.4%   
Current liabilities Rs m8,36533,081 25.3%   
Net working cap to sales %-88.437.1 -238.2%  
Current ratio x0.52.6 17.2%  
Inventory Days Days15687 179.0%  
Debtors Days Days6762 107.9%  
Net fixed assets Rs m14,480111,567 13.0%   
Share capital Rs m611,609 3.8%   
"Free" reserves Rs m903123,645 0.7%   
Net worth Rs m5,127125,254 4.1%   
Long term debt Rs m5,83236,454 16.0%   
Total assets Rs m19,433209,532 9.3%  
Interest coverage x-0.98.7 -10.6%   
Debt to equity ratio x1.10.3 390.8%  
Sales to assets ratio x0.30.7 38.0%   
Return on assets %2.05.7 34.4%  
Return on equity %-21.98.3 -264.6%  
Return on capital %3.68.5 42.8%  
Exports to sales %24.534.2 71.7%   
Imports to sales %10.28.3 122.1%   
Exports (fob) Rs m1,26450,050 2.5%   
Imports (cif) Rs m52512,203 4.3%   
Fx inflow Rs m1,53951,066 3.0%   
Fx outflow Rs m94217,678 5.3%   
Net fx Rs m59733,388 1.8%   
CASH FLOW
From Operations Rs m59923,824 2.5%  
From Investments Rs m-438-13,127 3.3%  
From Financial Activity Rs m-303-13,239 2.3%  
Net Cashflow Rs m-141-2,478 5.7%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.6 12.2 4.9%  
FIIs % 1.3 23.7 5.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.6 26.2 90.1%  
Shareholders   10,259 161,166 6.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Metal Stocks Drag(09:30 am)

Asian share markets slipped in the opening trade today as investors digested the escalation in trade tensions between the US and China after both countries announced tariffs last week.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jun 18, 2018 11:37 AM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - STERLING BIOTECH COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS